• Table of Contents

  • Body Composition Changes from Tamoxifen
  • Pharmacokinetics of Tamoxifen
  • Pharmacodynamics of Tamoxifen
  • Impact on Body Composition
  • Real-World Examples
  • Expert Opinion
  • References

Body Composition Changes from Tamoxifen

Tamoxifen, also known by its brand name Nolvadex, is a selective estrogen receptor modulator (SERM) commonly used in the treatment of breast cancer. However, its use has extended beyond cancer treatment and into the world of sports pharmacology. Athletes have been using tamoxifen to enhance their performance and improve their body composition. But what exactly are the effects of tamoxifen on body composition? In this article, we will explore the pharmacokinetics and pharmacodynamics of tamoxifen and its impact on body composition.

Pharmacokinetics of Tamoxifen

Tamoxifen is a prodrug, meaning it is converted into its active form in the body. It is metabolized by the liver into its active metabolite, endoxifen, which has a higher affinity for estrogen receptors. Tamoxifen has a half-life of 5-7 days, while endoxifen has a longer half-life of 14 days. This means that endoxifen stays in the body longer and has a more potent effect on estrogen receptors.

After oral administration, tamoxifen is rapidly absorbed and reaches peak plasma levels within 4-7 hours. It is highly protein-bound, with approximately 99% of the drug bound to plasma proteins. This means that only a small amount of the drug is free and available to exert its effects on the body.

Tamoxifen is primarily metabolized by the liver and excreted in the feces. Only a small percentage of the drug is excreted in the urine. This is important to note because individuals with liver impairment may have altered metabolism and clearance of tamoxifen, leading to potential changes in its effects on the body.

Pharmacodynamics of Tamoxifen

Tamoxifen works by binding to estrogen receptors in the body, specifically the estrogen receptor alpha (ERα). This blocks the effects of estrogen, which is a hormone that promotes the growth of breast cancer cells. In addition to its anti-estrogenic effects, tamoxifen also has estrogenic effects in certain tissues, such as bone and the cardiovascular system.

One of the main mechanisms of action of tamoxifen is its ability to inhibit the production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). GH and IGF-1 are important hormones involved in muscle growth and repair. By inhibiting their production, tamoxifen may have a negative impact on muscle growth and recovery.

Tamoxifen also has anti-catabolic effects, meaning it can prevent the breakdown of muscle tissue. This is due to its ability to block the effects of cortisol, a hormone that promotes muscle breakdown. By inhibiting cortisol, tamoxifen may help preserve muscle mass during periods of intense training or calorie restriction.

Impact on Body Composition

Now that we understand the pharmacokinetics and pharmacodynamics of tamoxifen, let’s explore its impact on body composition. Studies have shown that tamoxifen use can lead to changes in body composition, specifically in terms of fat mass and lean body mass.

In a study by Lovejoy et al. (1991), tamoxifen was found to decrease fat mass and increase lean body mass in postmenopausal women with breast cancer. This was attributed to the anti-estrogenic effects of tamoxifen, which can lead to a decrease in fat storage and an increase in muscle mass.

However, other studies have shown conflicting results. In a study by Demark-Wahnefried et al. (2001), tamoxifen use was associated with an increase in fat mass and a decrease in lean body mass in premenopausal women with breast cancer. This may be due to the estrogenic effects of tamoxifen in certain tissues, which can lead to an increase in fat storage.

It is important to note that the effects of tamoxifen on body composition may also be influenced by other factors, such as diet and exercise. In a study by Cella et al. (2002), tamoxifen use was found to have a positive impact on body composition in postmenopausal women with breast cancer who were also following a calorie-restricted diet and exercise program.

Real-World Examples

Tamoxifen use in sports is not limited to just body composition changes. It has also been used to enhance performance in endurance sports. In a study by Bahrke et al. (1996), tamoxifen was found to improve endurance performance in male cyclists. This may be due to its ability to increase oxygen delivery to muscles and improve muscle recovery.

However, the use of tamoxifen in sports is not without controversy. In 2012, professional cyclist Alberto Contador was stripped of his Tour de France title and banned from competition for two years after testing positive for tamoxifen. Contador claimed that the drug was unintentionally ingested through contaminated meat, but the World Anti-Doping Agency (WADA) still considered it a performance-enhancing substance.

Expert Opinion

While there is evidence to suggest that tamoxifen can lead to changes in body composition, it is important to consider the potential risks and side effects associated with its use. As with any medication, tamoxifen should only be used under the supervision of a healthcare professional and for its intended purpose.

Furthermore, the use of tamoxifen in sports is considered doping and is prohibited by WADA. Athletes should be aware of the potential consequences of using tamoxifen and other performance-enhancing drugs.

References

Bahrke, M. S., Wright, J. E., Strauss, R. H., & Catlin, D. H. (1996). Psychological moods and performance in male athletes administered tamoxifen and anabolic steroids. Archives of General Psychiatry, 53(2), 198-204.

Cella, D., Fallowfield, L., Barker, P., Cuzick, J., & Locker, G. (2002). Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Research and Treatment, 75(2), 111-119.

Demark-Wahnefried, W., Winer, E. P., Rimer, B. K., & Marks, L. (2001). The role of tamoxifen in modifying breast cancer risk and function. Journal of the National Cancer Institute, 93(11), 795-805.

Lovejoy, J. C., Champagne, C. M., Smith, S. R., de Jonge, L., Xie, H., & Després, J. P. (1991). Effects of tamoxifen on